The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma.

ABSTRACT: The development of several treatment options over the last 2 decades has led to a notable improvement in the survival of patients with multiple myeloma. Despite these advances, the disease remains incurable for most patients. Moreover, standard combinations of alkylating agents, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies targeting CD38 and corticoids are exhausted relatively fast in a proportion of high-risk patients. Such high-risk patients account for over 20% of cases and currently represent a major unmet medical need. The challenge of drug resistance requires the development of highly active new agents with a radically different mechanism of action. Several immunotherapeutic modalities, including antibody-drug conjugates and T-cell engagers, appear to be p

SUBMITTER: Oriol A 

PROVIDER: S-EPMC8170343 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature